Description: LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to historically underserved patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets.
Home Page: www.lianbio.com
LIAN Technical Analysis
103 Carnegie Center Drive
Princeton,
NJ
08540
United States
Phone:
609 486 2308
Officers
| Name | Title |
|---|---|
| Mr. Konstantin Poukalov | Founder & Exec. Chairman |
| Dr. Yizhe Wang Ph.D. | CEO & Director |
| Dr. Debra Yu M.D. | Pres & Chief Strategy Officer |
| Ms. Yi Larson M.B.A. | CFO & Treasurer |
| Ms. Brianne Jahn | Chief Bus. Officer |
| Mr. Jiang Qian | China Gen. Mang. |
| Dr. Michael Humphries M.D. | Chief Scientific Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5401 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-11-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 107 |